INTRODUCTION
Bone avascular necrosis (AVN) is a common late complication after kidney transplantation (KT), with a reported incidence of 3% to 30% (1) (2) (3) (4) . AVN, a pathological condition defined as death of all cellular elements and progressive destruction of the bone, occurs because of bone vasculature disruption, death of osteocytes and fat cells, and bone architecture alterations (5, 6) . Generally, various factors such as corticosteroid administration, alcohol use, smoking, radiation, hyperlipidemia, thrombophlebitis, and intravascular coagulation have been proposed as risk factors for AVN throughout the population (7) (8) (9) . Joint pain radiating to buttocks, thighs, or knees while the patient bears their weight on the affected joint is the first and typical symptom of AVN (10) . Pain is presumed to be related to bone marrow edema that can be observed using magnetic resonance imag-tion to steroid regimen in relation to AVN development (3, (12) (13) (14) (15) (16) . A study reported that higher cumulative steroid dose, high blood urea nitrogen levels, immunosuppressive drug treatment, and impaired blood flow caused by arterial ischemia and/or venous thrombosis were potential risk factors for AVN (12) . A recent report indicated that steroid administration within 2 weeks after KT exhibited a dose-dependent relationship with AVN development (3) . Treatment with calcineurin inhibitors, mycophenolate mofetil, cyclosporine, or sirolimus, acute rejection, and female sex were also suggested as risk factors for AVN development after transplantation (13) (14) (15) (16) .
Recently, KTs across immunologic barriers, such as flowcytometry cross matching (FCXM)-positive KT and ABOincompatible KT, have been increasingly performed. Under such circumstances, use of higher doses of immunosuppressive drugs and additive treatment for pretransplant desensitization are expected based on immunological risks. Additionally, the number of patients receiving steroid pulse treatments due to acute rejection are expected to increase. In this retrospective study, we determined the incidence of AVN after KT and investigated the risk factors associated with AVN development with regard to recent transplantation trends.
MATERIALS AND METHODS
This was a retrospective observational study that included data from patient medical record reviews. The study protocol was approved by the Institutional Review Board of Asan Rejection-free graft survival was defined as the time taken from transplantation to acute rejection and was pathologically diagnosed according to the Banff criteria (17) . 
AVN evaluation was conducted in patients with typical
AVN symptoms such as movement restriction, pain, or disturbance in walking. AVN was diagnosed using magnetic resonance imaging findings (4, 18) and clinical diagnosis according to current guidelines, and the diagnosis was conducted by orthopedic surgeons at our institution (19) . The Data are presented as number (%) or mean±SD. Abbreviation: AVN, avascular necrosis. Rejection-free survival rate was measured using the Kaplan-Meier method and was compared using the log-rank test.
All other statistical analyses were performed using the SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA), and P≤0.05 was considered statistically significant. Table 1 . There were significantly more female patients (P=0.02) and a significantly higher end-stage renal disease prevalence because of hypertension (P=0.01) among patients with AVN. Mean cumulative steroid dose during the last follow-up in patients without AVN (9,108±3,400 mg) was higher than that in patients with AVN (4,483±1,114 mg) until AVN occurrence (P＜0.01). More patients in the AVN group (n=4, 12.1%) received steroid pulse treatment due to biopsy-proven rejection during the first 6 months after KT than patients without AVN did (n=68, 4.4%; P=0.04).
RESULTS
AVN was diagnosed at a mean of 13.9±6.6 months after KT (range, 5 to 29) (Fig. 1) (Table 3 ). However, no significant difference in rejection-free graft survival rates between patients with AVN and without AVN were observed (P=0.67) (Fig. 2) .
DISCUSSION
The incidence of symptomatic AVN in this retrospective study was 2.1% among patients that underwent KT. Additionally, female sex and steroid pulse treatment within 6 months after KT were independent risk factors for AVN development. The AVN incidence observed in the current study agrees with the reported 5.1% to 6% incidence among patients undergoing low-dose steroid treatment in recent studies (3, 14) . Shibatani et al.(20) and Saito et al.(3) reported that the steroid dose in the early postoperative period Activation of intravascular coagulation has been suggested as an important event leading to ischemia (6) , which causes disruption of bone vasculature and bone marrow, leading to ischemic necrosis of bony tissues and bone collapse(21).
Patients exposed to higher corticosteroid doses or those who underwent corticosteroid treatment for longer durations were considered to be at a higher risk for AVN (2, 22) .
Although several studies revealed that cumulative corticosteroid doses were higher among patients with AVN (14, 23) , the current study suggested that cumulative corticosteroid dose itself was not a risk factor for AVN development.
Steroid usage is evidently a major cause of AVN after KT;
however, not all recipients receiving steroids develop AVN.
In the current study, the mean duration from KT to AVN development was 13.9±6.6 months (range, 5 to 29) in the AVN group. Serrano et al. (22) recently reported an AVN-free survival rate that was similar to that obtained in the current study and found that the recipients who did not develop AVN were exposed to higher cumulative doses for A recent large, population-based study reported that AVN incidence was only 0.13% among patients treated with low-dose mPD of ＜15 to 20 mg/day (24 (15) reported that female sex significantly increased AVN risk after allogeneic hematopoietic stem cell transplantation and speculated that estrogen levels after transplantation could affect osteoclast and osteoblast activity.
A study using a rat model for AVN reported that female rats were more severely affected because of sexual dimorphisms in the coagulation system (26) . However, these studies did not clarify the exact mechanisms underlying sex-related differences in AVN occurrence. Further studies are warranted to explore the AVN pathogenesis in females.
The current study has several limitations. First, due to its retrospective nature, selection and information biases could not be ruled out. Second, the number of patients with AVN was relatively less. Third, AVN incidence might have been underestimated because only patients with symptomatic AVN underwent workup for AVN diagnosis. Finally, there might have been a lag time bias because diagnosis and treatment was performed only in patients with AVN symptoms.
CONCLUSION
Steroid pulse treatment within 6 months of KT and female sex were independent risk factors for AVN development.
The results of the current study provide valuable information for physicians who manage recipients after KT.
Although early steroid cessation and steroid avoidance should be considered in patients having low immunologic risk, proper desensitization and optimal immunosuppression to prevent acute rejection in highly sensitized patients can prevent AVN after KT. Further studies to determine sex-related differences in AVN development are warranted.
